Richard A Marshall1, Michael Buckstein1, Nelson N Stone2, Richard Stock3. 1. Department of Radiation Oncology, The Mount Sinai Medical Center, One Gustave L. Levy Place, New York, NY. 2. Department of Urology, The Mount Sinai Medical Center, One Gustave L. Levy Place, New York, NY. 3. Department of Radiation Oncology, The Mount Sinai Medical Center, One Gustave L. Levy Place, New York, NY. Electronic address: richard.stock@mountsinai.org.
Abstract
OBJECTIVES: To present our treatment algorithm and 20-year experience in treating prostate cancer with brachytherapy since 1990, with focus on cancer-control outcomes and treatment-related morbidity. METHODS AND MATERIALS: We selected patients treated for localized prostate cancer with brachytherapy, combination therapy with external beam radiotherapy, and adjuvant androgen deprivation therapy as prescribed by our Mount Sinai risk stratification and treatment algorithm. Outcomes were analyzed with respect to biochemical failure, distant metastases, prostate cancer-specific survival, and overall survival. Morbidity was assessed with respect to urinary, sexual, and rectal outcomes. RESULTS: In total, 2,495 patients met inclusion criteria. The 12-year actuarial freedom from biochemical failure was 83% (low risk: 90%, intermediate risk: 84%, and high risk: 64%); freedom from distant metastasis was 95%; prostate cancer-specific survival was 95%; and overall survival was 70%. On multivariate analysis, significant associations were found between cancer control and risk group, total biologically effective dose, and androgen deprivation therapy. With regard to morbidity, potency was preserved in 61%, and urinary symptoms improved in 35%. The 12-year actuarial freedom from urinary retention events was 90% and from severe rectal bleed was 93%. CONCLUSIONS: Brachytherapy, as administered via the Mount Sinai algorithm, remains an efficacious and benign treatment option for patients with localized prostate cancer of all risk groups.
OBJECTIVES: To present our treatment algorithm and 20-year experience in treating prostate cancer with brachytherapy since 1990, with focus on cancer-control outcomes and treatment-related morbidity. METHODS AND MATERIALS: We selected patients treated for localized prostate cancer with brachytherapy, combination therapy with external beam radiotherapy, and adjuvant androgen deprivation therapy as prescribed by our Mount Sinai risk stratification and treatment algorithm. Outcomes were analyzed with respect to biochemical failure, distant metastases, prostate cancer-specific survival, and overall survival. Morbidity was assessed with respect to urinary, sexual, and rectal outcomes. RESULTS: In total, 2,495 patients met inclusion criteria. The 12-year actuarial freedom from biochemical failure was 83% (low risk: 90%, intermediate risk: 84%, and high risk: 64%); freedom from distant metastasis was 95%; prostate cancer-specific survival was 95%; and overall survival was 70%. On multivariate analysis, significant associations were found between cancer control and risk group, total biologically effective dose, and androgen deprivation therapy. With regard to morbidity, potency was preserved in 61%, and urinary symptoms improved in 35%. The 12-year actuarial freedom from urinary retention events was 90% and from severe rectal bleed was 93%. CONCLUSIONS: Brachytherapy, as administered via the Mount Sinai algorithm, remains an efficacious and benign treatment option for patients with localized prostate cancer of all risk groups.
Authors: Martin T King; Paul L Nguyen; Ninjin Boldbaatar; Clare M Tempany; Robert A Cormack; Clair J Beard; Mark D Hurwitz; W Warren Suh; Anthony V D'Amico; Peter F Orio Journal: Cancer Date: 2018-07-05 Impact factor: 6.860
Authors: O Pons-Llanas; E Collado-Ballesteros; S Roldan-Ortega; A Conde-Moreno; F Celada-Alvarez; F Martínez-Arcelus; M J Pérez-Calatayud; V Carmona-Meseguer; J Gimeno-Olmos; V Forner-Ferrer; A Tormo-Micó; J Perez-Calatayud; J López-Torrecilla Journal: Rep Pract Oncol Radiother Date: 2020-05-08
Authors: Jose Luis Guinot; Jose Vicente Ricós; Maria Isabel Tortajada; Miguel Angel Santos; Juan Casanova; Jose Clemente; Josefa Samper; Paula Santamaría; Leoncio Arribas Journal: J Contemp Brachytherapy Date: 2015-08-18
Authors: Jim Rose; Derek Liu; Oleksandr Boychak; Ron Sloboda; Nadeem Pervez; Albert Murtha; Don Yee; John Amanie; Nawaid Usmani Journal: Cureus Date: 2017-05-12